Real-Life Impact of Glucocorticoid Treatment in COVID-19 Mortality : A Multicenter Retrospective Study
We aimed to determine the impact of steroid use in COVID-19 in-hospital mortality, in a retrospective cohort study of the SEMICOVID19 database of admitted patients with SARS-CoV-2 laboratory-confirmed pneumonia from 131 Spanish hospitals. Patients treated with corticosteroids were compared to patients not treated with corticosteroids; and adjusted using a propensity-score for steroid treatment. From March-July 2020, 5.262 (35.26%) were treated with corticosteroids and 9.659 (64.73%) were not. In-hospital mortality overall was 20.50%; it was higher in patients treated with corticosteroids than in controls (28.5% versus 16.2%, OR 2.068 [95% confidence interval; 1.908 to 2.242]; p = 0.0001); however, when adjusting by occurrence of ARDS, mortality was significantly lower in the steroid group (43.4% versus 57.6%; OR 0.564 [95% confidence interval; 0.503 to 0.633]; p = 0.0001). Moreover, the greater the respiratory failure, the greater the impact on mortality of the steroid treatment. When adjusting these results including the propensity score as a covariate, in-hospital mortality remained significantly lower in the steroid group (OR 0.774 [0.660 to 0.907], p = 0.002). Steroid treatment reduced mortality by 24% relative to no steroid treatment (RRR 0.24). These results support the use of glucocorticoids in COVID-19 in this subgroup of patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Journal of clinical medicine - 10(2021), 20 vom: 13. Okt. |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 26.10.2021 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/jcm10204678 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332229432 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332229432 | ||
| 003 | DE-627 | ||
| 005 | 20231225215151.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcm10204678 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1107.xml |
| 035 | |a (DE-627)NLM332229432 | ||
| 035 | |a (NLM)34682801 | ||
| 035 | |a (PII)4678 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Muñoz-Gómez, Ana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Real-Life Impact of Glucocorticoid Treatment in COVID-19 Mortality |b A Multicenter Retrospective Study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 26.10.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a We aimed to determine the impact of steroid use in COVID-19 in-hospital mortality, in a retrospective cohort study of the SEMICOVID19 database of admitted patients with SARS-CoV-2 laboratory-confirmed pneumonia from 131 Spanish hospitals. Patients treated with corticosteroids were compared to patients not treated with corticosteroids; and adjusted using a propensity-score for steroid treatment. From March-July 2020, 5.262 (35.26%) were treated with corticosteroids and 9.659 (64.73%) were not. In-hospital mortality overall was 20.50%; it was higher in patients treated with corticosteroids than in controls (28.5% versus 16.2%, OR 2.068 [95% confidence interval; 1.908 to 2.242]; p = 0.0001); however, when adjusting by occurrence of ARDS, mortality was significantly lower in the steroid group (43.4% versus 57.6%; OR 0.564 [95% confidence interval; 0.503 to 0.633]; p = 0.0001). Moreover, the greater the respiratory failure, the greater the impact on mortality of the steroid treatment. When adjusting these results including the propensity score as a covariate, in-hospital mortality remained significantly lower in the steroid group (OR 0.774 [0.660 to 0.907], p = 0.002). Steroid treatment reduced mortality by 24% relative to no steroid treatment (RRR 0.24). These results support the use of glucocorticoids in COVID-19 in this subgroup of patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a corticosteroids | |
| 650 | 4 | |a mortality | |
| 700 | 1 | |a Fernández-Cruz, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Lavilla-Olleros, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Giner-Galvañ, Vicente |e verfasserin |4 aut | |
| 700 | 1 | |a Ausín-García, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Wikman, Philip |e verfasserin |4 aut | |
| 700 | 1 | |a Bendala-Estrada, Alejandro D |e verfasserin |4 aut | |
| 700 | 1 | |a Vargas, Juan A |e verfasserin |4 aut | |
| 700 | 1 | |a Rubio-Rivas, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Laureiro, Jaime |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Bermúdez, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Buonaiuto, Verónica A |e verfasserin |4 aut | |
| 700 | 1 | |a Arenas de Larriva, Antonio P |e verfasserin |4 aut | |
| 700 | 1 | |a Pascual-Pérez, María de Los Reyes |e verfasserin |4 aut | |
| 700 | 1 | |a Alcalá-Pedrajas, José N |e verfasserin |4 aut | |
| 700 | 1 | |a Labirua-Iturburu Ruiz, Ane |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández-Milián, Almudena |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez Del Mazo, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Antequera, Beatriz |e verfasserin |4 aut | |
| 700 | 1 | |a Mella-Pérez, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Navas-Alcántara, María de la Sierra |e verfasserin |4 aut | |
| 700 | 1 | |a Soto-Delgado, Juan F |e verfasserin |4 aut | |
| 700 | 1 | |a Gámez-Mancera, Rosa M |e verfasserin |4 aut | |
| 700 | 1 | |a Sardiña-González, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Meijide-Míguez, Héctor |e verfasserin |4 aut | |
| 700 | 1 | |a Ramos-Rincón, José M |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez-Huelgas, Ricardo |e verfasserin |4 aut | |
| 700 | 1 | |a On Behalf Of The Semi-Covid-Network |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical medicine |d 2012 |g 10(2021), 20 vom: 13. Okt. |w (DE-627)NLM230666310 |x 2077-0383 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2021 |g number:20 |g day:13 |g month:10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/jcm10204678 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2021 |e 20 |b 13 |c 10 | ||